Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Macular Edema: full-pipeline trial registry
1 of 15 indexed Macular Edema trials are currently recruiting.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 1 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Macular Edema: 15 US clinical trials tracked, 1 recruiting.
Macular Edema is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is JHSPH Center for Clinical Trials, running 2 of these trials.
Enrollment posture brief
Registry condition macular-edema
OPEN 1 | RECR 7% | LATE 5 | EARLY 7 | RANK #1140 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Liver Disease (7% recruiting · 15 trials)
Macular Edema lists 1 open slots (7% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Macular Edema on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Macular Edema is recruiting below its size-band peers.
1 of 15 indexed trials (6.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Macular Edema trials is spread across many organizations.
JHSPH Center for Clinical Trials accounts for 2 of 15 trials (13.3%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most Macular Edema trials plan to enrol fewer than 100 people.
Median target enrolment is 32 among the 15 trials that report a genuine target (sentinel values excluded). 9 of those (60%) plan for fewer than 100 participants.
-
Macular Edema research is mostly interventional.
14 interventional and 1 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
Boehringer Ingelheim
NCT06962839
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
AiViva BioPharma
NCT05698329
Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage
National Eye Institute (NEI)
NCT00106132
A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion
Genentech
NCT01277302
Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
JHSPH Center for Clinical Trials
NCT02623426
PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial
JHSPH Center for Clinical Trials
NCT02374060
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
Barnes Retina Institute
NCT01428388
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
AbbVie
NCT04976777
Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO
Optos
NCT01692938
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
Long Island Vitreoretinal Consultants
NCT01231633
Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
Clearside Biomedical
NCT02255032
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
Novartis Pharmaceuticals
NCT04635800
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
Retina Vitreous Associates of Florida
NCT01476449
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Retina Associates of Florida, P.A.
NCT01247220
Intravitreal Aflibercept Injection for Radiation Retinopathy
Washington University School of Medicine
NCT01579760
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
| Phase 3 | 4 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Macular Edema records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Macular Edema trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Macular Edema page
15 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Macular Edema trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- JHSPH Center for Clinical Trials sponsors the most Macular Edema trials on record, review their full trial history before evaluating a specific study. See JHSPH Center for Clinical Trials's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Macular Edema condition card totals 15 registered trials; most-linked intervention Ranibizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.